Postmarketing Surveillance of Drug-Induced Liver Injury

  • S. Christopher JonesEmail author
  • Cindy Kortepeter
  • Allen D. Brinker
Part of the Methods in Pharmacology and Toxicology book series (MIPT)


Background Most clinical trials that support approval are not adequately powered to detect rare adverse reactions (e.g., drug-induced liver injury, Stevens–Johnson syndrome, and others) that may emerge under real-world use of a drug. The US Food and Drug Administration (FDA) and other global drug regulatory bodies conduct postmarketing surveillance for these types of adverse events.

FDA Methods FDA’s Center for Drug Evaluation and Research (CDER)—Division of Pharmacovigilance (DPV) is devoted to postmarketing adverse event surveillance for drug-induced liver injury (DILI) and other adverse events. DPV predominantly relies on clinical assessment of spontaneous reports submitted to the FDA Adverse Event Reporting System (FAERS) and published case reports to assess for DILI in the postmarketing setting. DPV uses criteria established by the Drug-Induced Liver Injury Network (DILIN), and others, to assess cases for causality and severity. In the past, the FDA has collaborated with professional groups with an interest in DILI to improve the quality of case reports. DPV also uses disproportionality and reporting rate analyses to detect and assess potential safety signals. Additionally, DPV collaborates with CDER epidemiologists who conduct analyses to refine DILI signals that emerge from surveillance.

Conclusion DILI continues to be a significant concern for marketed drugs and a leading cause of drug withdrawal from the worldwide market. Because events such as DILI are rare, systems such as those described in this chapter are important components of postmarketing surveillance, which is designed to recognize liver injury that may have gone undetected in a clinical development program for a drug.

Key words

Drug-induced liver injury Postmarket Surveillance Epidemiology Drug safety Causality assessment Hepatotoxicity Drug toxicity Adverse event 



The views expressed are those of the authors and do not necessarily represent the position of, nor imply endorsement from, the US Food and Drug Administration or the US Government.


  1. 1.
    World Health Organization. Available via Accessed 22 Jan 2017
  2. 2.
    Council for International Organization of Medical Sciences (CIOMS) Report of Working Group VIII (2010). Practical aspects of signal detection in Pharmacovigilance. Geneva, Switzerland, 14Google Scholar
  3. 3.
    Avigan MI, Mozersky RP, Seeff LB (2016) Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States. Int J Mol Sci 17(3):331CrossRefGoogle Scholar
  4. 4.
    United States Food and Drug Administration (2009). Guidance for industry drug-induced liver injury: premarketing clinical evaluation. Accessed 11 Jan 2017
  5. 5.
    WITHDRAWN: a resource for withdrawn and discontinued drugs. Accessed 9 Feb 2017
  6. 6.
    Siramshetty VB, Nickel J, Omieczynski C, Gohlke B-O, Drwal MN (2015) Robert Preissner; WITHDRAWN—a resource for withdrawn and discontinued drugs. Nucleic Acids Res 44(D1):D1080–D1086. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bell LN, Chalasani N (2009) Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 29(4):337–347CrossRefGoogle Scholar
  8. 8.
    Navarro VJ, Senior JR (2006) Drug-related hepatotoxicity. N Engl J Med 354(7):731–739CrossRefGoogle Scholar
  9. 9.
    Philips B (2005) Towards evidence based medicine for paediatricians. Arch Dis Child 90:642–650CrossRefGoogle Scholar
  10. 10.
    US Food and Drug Administration-MedWatch Program. Available at Accessed 13 Feb 2017
  11. 11.
    US Government General Accounting Office. General Accounting Office Report on Adverse Drug Events Substantial Problem but Magnitude Uncertain, 1 Feb 1 2000. Accessed 22 Jan 2017
  12. 12.
    McAdams M, Staffa J, Dal Pan G (2008) Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 17:229–239CrossRefGoogle Scholar
  13. 13.
  14. 14.
    Munoz MA, Kulick CG, Kortepeter CM, Levin RL, Avigan MI (2017) Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler J.
  15. 15.
    Drugs@FDA updated prescribing information for Tecfidera. Accessed 30 Mar 2017
  16. 16.
    US Food and Drug Administration. Drug safety communication, July 26, 2013. Accessed 22 Jan 2017
  17. 17.
    Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH (1999) A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 48:847–852CrossRefGoogle Scholar
  18. 18.
    Ball R, Robb M, Anderson SA, Dal Pan G (2016) The FDA’s sentinel initiative-a comprehensive approach to medical product surveillance. Clin Pharmacol Ther 99(3):265–267CrossRefGoogle Scholar
  19. 19.
    US Food and Drug Administration-Sentinel Initiative. Accessed 13 Feb 2017
  20. 20.
    Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med 368(14):1272–1274CrossRefGoogle Scholar
  21. 21.
    Lo Re V III, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KB, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Selvam N, Cooper WO, Selvan MS, VanWormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A (2013) Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's mini-sentinel distributed database. Pharmacoepidemiol Drug Saf 22(8):861–872CrossRefGoogle Scholar
  22. 22.
    Lo Re V III, Carbonari DM, Forde KA, Goldberg D, Lewis JD, Haynes K, Leidl KB, Reddy RK, Roy J, Sha D, Marks AR, Schneider JL, Strom BL, Corley DA (2015) Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. Pharmacoepidemiol Drug Saf 24(7):676–683CrossRefGoogle Scholar
  23. 23.
    Major JM, Zhou EH, Wong HL, Trinidad JP, Pham TM, Mehta H, Ding Y, Staff JA, Iyasu S, Wang C, Willy ME (2016) Trends in rates of acetaminophen-related adverse events in the United States. Pharmacoepidemiol Drug Saf 25:590–598CrossRefGoogle Scholar
  24. 24.
    Brauer R, Douglas I, Garcia Rodriguez LA, Downey G, Huerta C, de Abajo F, Bate A, Tepie MF, de Groot MCH, Schlienger R, Reynolds R, Smeeth L, Klungel O, Ruigomez A (2016) Risk of acute liver injury associated the use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. Pharmacoepidemiology. Drug Saf 25(suppl 1):29–38Google Scholar
  25. 25.
    World Health Organization-Uppsala Monitoring Centre. Accessed 13 Feb 2017
  26. 26.
    Bearden DT, Neuhauser MM, Garey KW (2001) Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy 21(10):1204–1222CrossRefGoogle Scholar
  27. 27.
    Aventis. Ketek (telithromycin): Briefing document for the FDA Anti-Infective Drug Products Advisory Committee Meeting. January 2003. Accessed 3 Feb 2017 at
  28. 28.
    Soreth J. Ketek (telithromycin) NDA background for the FDA anti-infective drug products advisory committee meeting (2003). Accessed 3 Feb 2017 at
  29. 29.
    Cooper C. Medical officer safety review of NDA 21–144: telithromycin (Ketek), 31 Mar 2004. Accessed 3 Feb 2017 at
  30. 30.
    Ross DB (2007) The FDA and the case of Ketek. N Engl J Med 356(16):1601–1604CrossRefGoogle Scholar
  31. 31.
    Senior JR (2009) Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin Pharmacol Ther 85(3):331–334CrossRefGoogle Scholar
  32. 32.
    FDA Public Health Advisory for Ketek (telithromycin). 20 Jan 2006. Accessed 3 Feb 2017 at
  33. 33.
    Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP III, Banks PM (2006) Brief communication: severe hepatatoxicity of telithromycin: three case reports and literature review. Ann Intern Med 144:415–420CrossRefGoogle Scholar
  34. 34.
    Soreth J, Cox E, Kweder S, Jenkins J, Galson S (2007) Ketek - the FDA perspective. N Engl J Med 356(16):1675–1676CrossRefGoogle Scholar
  35. 35.
    Brinker A, Wassel R. Telithromycin-associated hepatotoxicity. 14 Dec 2006. Accessed 3 Feb 2017 at
  36. 36.
    Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB (2009) Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49(1):250–257CrossRefGoogle Scholar
  37. 37.
    Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH, DILIN Research Group (2011) Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 9(6):517–523CrossRefGoogle Scholar
  38. 38.
    Brinker A, Goldkind L, Bonnel R, Beitz J (2004) Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 21(7):479–484CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • S. Christopher Jones
    • 1
    Email author
  • Cindy Kortepeter
    • 1
  • Allen D. Brinker
    • 1
  1. 1.Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and ResearchU.S. Food and Drug AdministrationSilver SpringUSA

Personalised recommendations